What is the recommended dose of anti-tubercular (anti-tuberculosis) drugs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anti-Tubercular Drug Dosing

For drug-susceptible tuberculosis in adults, use isoniazid 5 mg/kg (max 300 mg), rifampin 10 mg/kg (max 600 mg), pyrazinamide 15-30 mg/kg (max 2000 mg), and ethambutol 15-25 mg/kg (max 2500 mg) daily; for children, use isoniazid 10-15 mg/kg (max 300 mg), rifampin 10-20 mg/kg (max 600 mg), pyrazinamide 30-40 mg/kg (max 2000 mg), and ethambutol 15-25 mg/kg (max 2500 mg) daily. 1, 2, 3, 4

Drug-Susceptible TB: First-Line Agents

Daily Dosing Regimen

Adults:

  • Isoniazid: 5 mg/kg daily (maximum 300 mg) 1, 2, 4
  • Rifampin: 10 mg/kg daily (maximum 600 mg) 1, 2, 3
  • Pyrazinamide: 15-30 mg/kg daily (maximum 2000 mg per CDC; 3000 mg per FDA label) 1, 2, 5
  • Ethambutol: 15-25 mg/kg daily (maximum 2500 mg) 1, 2

Children:

  • Isoniazid: 10-15 mg/kg daily (maximum 300 mg) 1, 2, 4
  • Rifampin: 10-20 mg/kg daily (maximum 600 mg) 1, 2, 3
  • Pyrazinamide: 30-40 mg/kg daily (maximum 2000 mg) 1, 2
  • Ethambutol: 15-25 mg/kg daily (maximum 2500 mg) 1, 2

Intermittent Dosing (Twice-Weekly)

Adults:

  • Isoniazid: 15 mg/kg (maximum 900 mg) 1, 2
  • Rifampin: 10 mg/kg (maximum 600 mg) 1, 2
  • Pyrazinamide: 50-70 mg/kg 1, 5
  • Ethambutol: 50 mg/kg 1, 2

Children:

  • Isoniazid: 20-30 mg/kg (maximum 900 mg) 1, 2
  • Rifampin: 10-20 mg/kg (maximum 600 mg) 1, 2
  • Pyrazinamide: 50-70 mg/kg (maximum 3000 mg) 1, 2
  • Ethambutol: 50 mg/kg (maximum 2500 mg) 1, 2

Intermittent Dosing (Thrice-Weekly)

Adults:

  • Isoniazid: 15 mg/kg (maximum 900 mg) 1, 2
  • Rifampin: 10 mg/kg (maximum 600 mg) 1, 2
  • Pyrazinamide: 30-40 mg/kg 1
  • Ethambutol: 25-35 mg/kg 1

Multidrug-Resistant TB: Second-Line Agents

Group 1: Fluoroquinolones (Highest Priority)

  • Levofloxacin: 750-1000 mg daily in adults; 15-20 mg/kg daily in children 1, 2
  • Moxifloxacin: 400 mg daily in adults (some use 600-800 mg); 10-15 mg/kg daily in children 1, 2

Group 2: Newer Agents

  • Bedaquiline: 400 mg daily for 14 days, then 200 mg three times weekly in adults and children >12 years and >30 kg; for children 6-12 years and 15-30 kg, use half the adult dose (200 mg daily for 2 weeks, then 100 mg three times weekly) 1
  • Linezolid: 600 mg daily in adults and children >12 years (10 mg/kg); for children <12 years, use weight-based dosing: 5-9 kg: 15 mg/kg, 10-23 kg: 12 mg/kg, >23 kg: 10 mg/kg 1

Group 3: Other Core Agents

  • Clofazimine: 100 mg daily in adults; 2-5 mg/kg daily in children 1, 2
  • Cycloserine/Terizidone: 15-20 mg/kg daily (usually 250-500 mg once or twice daily) in adults; 15-20 mg/kg daily in children 1, 2

Group 4: Injectable Agents

  • Amikacin: 15 mg/kg daily (some prefer 25 mg/kg three times weekly) in adults; 15-20 mg/kg daily in children 1, 2
  • Streptomycin: 15 mg/kg daily (some prefer 25 mg/kg three times weekly) in adults; 15-20 mg/kg daily or 25-30 mg/kg twice weekly in children 1, 2

Group 5: Additional Agents

  • Delamanid: 100 mg twice daily in adults and children >35 kg; 50 mg twice daily for children 6+ years and 20-34 kg; 25 mg twice daily for children 3-5 years and 10-20 kg 1
  • Ethionamide/Prothionamide: 15-20 mg/kg total daily (usually 250-500 mg once or twice daily) in adults; 15-20 mg/kg total daily (divided 1-2 times daily) in children 1, 2

Critical Dosing Considerations

Weight-Based Adjustments

Dosing should be based on actual body weight for non-obese patients. For obese patients (>20% above ideal body weight), use ideal body weight or modified ideal body weight (IBW + [0.40 × (actual weight – IBW)]) for initial dosing, with consideration for therapeutic drug monitoring. 1, 2

Renal Impairment

  • Levofloxacin: Reduce to three times weekly dosing when GFR <30 mL/min 1, 6
  • Moxifloxacin: No dose adjustment needed 1, 6
  • Aminoglycosides (amikacin, streptomycin): Reduce frequency to 2-3 times weekly to allow drug clearance 1
  • Cycloserine: Start with 250 mg daily and verify with therapeutic drug monitoring 1
  • Pyrazinamide: Reduce to three times weekly dosing 1

Hepatic Impairment

Standard doses can be used with frequent monitoring of liver function tests. 2 In patients with pre-existing liver disease but normal liver enzymes, all anti-tuberculosis drugs may be used with close monitoring. 7

Special Populations

Pregnancy: All first-line drugs (rifampin, isoniazid, ethambutol, pyrazinamide) can be used during pregnancy. Streptomycin should be avoided due to fetal ototoxicity. Add prophylactic pyridoxine 10-25 mg daily. 2, 4, 7

HIV Co-infection: Use standard short-course chemotherapy doses, but be aware of drug interactions with antiretroviral therapy, particularly rifampin with protease inhibitors and NNRTIs. Therapeutic drug monitoring may be necessary due to malabsorption risk. 2, 7

Diabetes Mellitus: Use standard regimen with strict glucose control. Doses of oral hypoglycemic agents may need to be increased due to rifampin interaction. Add prophylactic pyridoxine. 7

Common Pitfalls and Caveats

Pyridoxine supplementation (25-50 mg daily) should be given with isoniazid to all persons at risk of neuropathy, including pregnant women, breastfeeding infants, persons with HIV, patients with diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age. 2

The fourth drug (ethambutol) in the initial phase can be omitted only when there is <4% primary isoniazid resistance in the community, no previous TB treatment, no exposure to drug-resistant cases, and the patient is not from a high-prevalence drug-resistant area. 1, 8 However, most experts recommend including ethambutol in all initial regimens due to difficulty in accurately assessing resistance risk. 1

For MDR-TB, at least four drugs to which the organism is likely susceptible must be used, with stepwise selection through the five drug groups based on efficacy, safety, and cost. 1, 9 Treatment of MDR-TB should be managed by physicians with specialized experience and access to quality-controlled drug susceptibility testing. 7

Fixed-dose combinations minimize the risk of selective drug intake and monotherapy, which can lead to acquired drug resistance. 7 All intermittent regimens (twice or thrice weekly) should be administered as directly observed therapy. 4, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

TB Medication Dosing Per Kilogram Body Weight

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Moxifloxacin Dosing in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.